ERBB2 and breast carcinoma: In August 2022, the United States Food and Drug Administration (FDA) approved T-Dxd for the treatment of patients with unresectable or advanced HER2-positive breast cancer who have previously been treated with an anti-HER2-based regimen and have developed disease recurrence during or within 6 months of completing therapy [78,79].